
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,290.0 million
Deal Type : Collaboration
Magnet Biomedicine, Lilly Partner to Develop Novel Molecular Glue Medicines
Details : The collaboration seeks to discover, develop, and commercialize molecular glue therapeutics for oncology by utilizing Magnet's TrueGlue discovery platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $40.0 million
February 28, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,290.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Newpath Partners
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The financing will support Magnet's approach to the discovery and development of TrueGlues™, compounds inducing cooperative protein-protein interactions and will advance its portfolio spanning several indications, including oncology, cardiovascular, an...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Newpath Partners
Deal Size : $50.0 million
Deal Type : Series A Financing
